GSK halts breast cancer trial following positive results

Share this article:
GlaxoSmithKline halted trials of its breast cancer drug Tykerb in women whose cancer had spread to other body parts because of good results, the UK drug maker said. Tykerb showed a 50% slowdown of the progression of advanced breast cancer in women who have failed on ordinary chemotherapy and Herceptin. “A pre-planned interim analysis of 321 patients in the study yielded statistically significant results, exceeding the primary endpoint,” GlaxoSmithKline said in a statement. GlaxoSmithKline said it plans to file for regulatory approval for Tykerb in the US and Europe later this year.
Share this article:
You must be a registered member of MMM to post a comment.

Does a health psychology approach hold the key to Rx adherence? In MM&M's latest Leadership Exchange Uncut eBook, industry stakeholders from the payer, provider, academic and pharma realms explore the "why" behind medicine taking. Access here.